Stoky
Back to explore
N
NoahListening
A
AshListening
0:00 / 0:00I. Material Agreement with Japan BCG Laboratory – Exclusive U.S. Rights to Tokyo-172 BCG
IBRX logo

ImmunityBio Secures Exclusive U.S. Rights to Tokyo-172 BCG Following Phase III Trial Showing 18% Lower Recurrence Risk

IBRX8-KFiling Date: 5/18/2026
ImmunityBio, Inc.
Description

What this story covers

ImmunityBio secured exclusive U.S. rights to the Tokyo-172 BCG strain after Phase III data demonstrated non-inferiority and a 64% five-year survival rate, positioning the company to resolve the national BCG shortage and expand its bladder cancer platform.

Story snapshot

CompanyImmunityBio, Inc.
TickerIBRX
VariantStandard detailed
Duration5:48
Filing type8-K
PeriodN/A
IndustryHealthcare & Pharmaceuticals
Accession0001193125-26-229153
Sources1

Full Story Script

Content not available for this story.

Primary Sources

sec_filing8-KView on SEC.gov →

Ask Noah

Question the story, source filings, and key financial signals.

Sign in to chat with Noah

Ask questions about revenue, margins, risk factors, filings and more. Noah uses retrieval-augmented analysis over raw financial disclosures.

Sign in